MMAF-Ome is a methoxyl analogue of MMAF, used in antibody-drug conjugates (ADCs) as the antimitotic agent part. The methoxyl works as the reaction group. MMAF is a potent auristatin-derived antineoplastic agent, working by inhibition of tubulin polymerization. It exhibited cytotoxicity in Karpas 299, H3396, 786-O and Caki-1 cells with IC50 values of 119nM, 105nM, 257nM and 200nM after 96-hour treatment.
Structure of 863971-12-4
* For research and manufacturing use only. We do not sell to patients.
Size | Price | Stock | Quantity |
---|---|---|---|
-- | $-- | In stock |
Looking for different specifications? Click to request a custom quote!
Capabilities & Facilities
Catalog | Product Name | CAS | Inquiry |
---|---|---|---|
BADC-01432 | Cys-MC-MMAF | 1160590-05-5 | |
BADC-00592 | MC-Alkyl-Hydrazine Modified MMAF | 1404071-64-2 | |
BADC-01455 | Modified MMAF-C5-COOH | 1404071-65-3 | |
BADC-00594 | PEG4-aminooxy-MMAF | 1415246-35-3 | |
BADC-00320 | MMAF Hydrochloride | 1415246-68-2 | |
BADC-00617 | MMAF sodium | 1799706-65-2 | |
BADC-01460 | DBM-MMAF | 1810001-93-4 | |
BADC-00863 | DBCO-PEG4-Val-Cit-PAB-MMAF | 2244602-23-9 | |
BADC-00751 | DBCO-PEG4-MMAF | 2360411-65-8 | |
BADC-00318 | MMAF | 745017-94-1 |
Contact our experts today for pricing and comprehensive details on our ADC offerings.
From cytotoxin synthesis to linker design, discover our specialized services that complement your ADC projects.
Learn more about payload design, linker strategies, and integrated CDMO support through our curated ADC content.
Find exactly what your project needs from our expanded range of ADCs, offering flexible options to fit your timelines and goals.